Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide vs dulaglutide on cardiovascular outcomes in type 2 diabetes (I8F-MC-GPGN(a), China)
CTR20200498Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2020
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of tirzepatide in type 2 diabetes mellitus (T2DM), cardiac morbidity, sponsored by Eli Lilly and Company. Started Sep 2020; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)cardiac morbidity
Beyond the preview
Go deeper on CTR20200498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200498.